BIONXT RECEIVES DELIVERY OF PREMIUM COMMERCIAL COATING AND CUTTING EQUIPMENT FOR COMMERCIAL MANUFACTURING OF DRUG DELIVERY PRODUCTS
VANCOUVER, BC – December 12, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to announce that it has received delivery of state-of-the-art coating and cutting equipment necessary for the buildout of commercial manufacturing capacity at its Vektor Pharma TF GmbH (“Vektor”) facility in Baden-Württemberg, Germany.
The German-designed and manufactured coating machine is fully automated with sensor-controlled coating thickness measurement capability. The cutting machine is also German-designed and manufactured and includes fully automated and camera-controlled laser cutting and pick and place robot automation. Both machines are CE certified under European health, safety, and environmental protection standards. The equipment is designed to manufacture the Company’s oral dissolvable (“ODF”) and transdermal (“TDS”) drug formulation products.
“BioNxt is focused on expedited development of its lead ODF and TDS drug formulations. With these products advancing toward commercialization and with potential contract development and manufacturing opportunities available, the Company is committed to achieving in-house commercial manufacturing capability as soon as possible,” said Hugh Rogers, BioNxt CEO & Director.
BioNxt’s wholly owned subsidiary, Vektor, is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of innovative, non-invasive drug delivery systems, particularly transdermal patches and sub-lingual strips for the delivery of active pharmaceutical ingredients for the treatment of pain and neurological conditions. According to Precedence Research, the global pharmaceutical drug delivery market size was valued at USD 1,525 billion in 2022 and expected to surpass approximately USD 2,047 billion by 2030.